

**tadalafil 2.5mg and 5mg film-coated tablets (Cialis®)**  
**(No: 554/09)**

**Lilly UK**

**Product Update**

08 May 2009

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**tadalafil 2.5mg and 5mg tablets (Cialis®)** are accepted for use in NHS Scotland for regular once-daily administration in patients with erectile dysfunction responding to an on-demand regimen of tadalafil who anticipate frequent use (at least twice weekly).

Compared with this level of on-demand use, the low dose regular regimen is expected to be cost-neutral overall.

Tadalafil represents an alternative to other phosphodiesterase type 5 inhibitors, primarily for patients for whom the longer duration of action represents a significant advantage. This drug is subject to the same NHS prescribing restrictions as other drug treatments for erectile dysfunction in terms of National Health Service (General Medical Services) (Scotland) Regulations.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 20 March 2009.*

**Chairman,  
Scottish Medicines Consortium**